{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:02:20Z","timestamp":1792648940228,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013501","name":"INCA","doi-asserted-by":"crossref","award":["grant PLBIO n\u00b0 14-197"],"award-info":[{"award-number":["grant PLBIO n\u00b0 14-197"]}],"id":[{"id":"10.13039\/100013501","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Targeting angiogenesis has been and continues to be an attractive therapeutic modality in glioblastoma (GBM) patients<jats:bold>.<\/jats:bold> However, GBM rapidly becomes refractory to anti-VEGF therapies. Myeloid cell infiltration is an important determinant of tumor progression. Given that VEGF is a modulator of the innate immune response we sought to analyze the dynamics of this response in a mouse model of GBM undergoing anti-VEGF therapy.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We grafted GL261-DsRed cells in transgenic Thy1-CFP\/\/LysM-EGFP\/\/CD11c-EYFP reporter mice. We combined recurrent spectral two-photon imaging with multiparametric cytometry, immunostaining, and brain clearing to characterize at two critical stages of tumor development (day 21 and day 28 after tumor grafting) the nature and spatial distribution of the innate response in control and bevacizumab-treated mice.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We report that at an early stage (21\u2009day), VEGF blockade has a detectable effect on the number of microglial cells but only a mild effect on the number of infiltrating myeloid cells. At a later stage (day 28), the treatment resulted in a specific adjustment of dendritic cell subsets. In treated mice, the number of monocytes and their monocyte-derived dendritic cells (moDC) progeny was increased by approximately twofold compared to untreated mice. In agreement, by in vivo quantitative imaging, we observed that treatment increased the number of LysM-EGFP cells traveling in tumor blood vessels and doubled the densities of both infiltrated LysM-EGFP monocytes and double-labeled EGFP\/EYFP moDC. The treatment also led to an increased density of conventional cDCs2 subset together with a decrease of cDCs1 subset, necessary for the development of anti-tumor immunity. Finally, we describe differential spatial cell distributions and two immune cell-traveling routes into the brain. LysM-EGFP cells distributed as a gradient from the meninges towards the tumor whereas CD11c-EYFP\/MHCII<jats:sup>+<\/jats:sup> cells were located in the basal area of the tumor. Brain clearing also revealed a flow of CD11c-EYFP cells following the corpus callosum.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We uncovered new features in the dynamics of innate immune cells in GBM-bearing mice and deciphered precisely the key populations, i.e., DC subsets controlling immune responses, that are affected by VEGF blockade. Since despite differences, human pathogenesis presents similarities with our mouse model, the data provide new insights into the effect of bevacizumab at the cellular level.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12974-019-1563-8","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T11:09:06Z","timestamp":1572260946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effects of VEGF blockade on the dynamics of the inflammatory landscape in glioblastoma-bearing mice"],"prefix":"10.1186","volume":"16","author":[{"given":"Aur\u00e9lie","family":"Soub\u00e9ran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Brustlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gouarn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Chasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Tchoghandjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Malissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Rougon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,28]]},"reference":[{"key":"1563_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/359845a0","volume":"359","author":"KH Plate","year":"1992","unstructured":"Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845\u20138.","journal-title":"Nature."},{"key":"1563_CR2","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:4733\u201340.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1563_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709\u201322.","journal-title":"N Engl J Med"},{"key":"1563_CR4","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Sulman EP, Mehta MP. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:2048\u20139.","journal-title":"N Engl J Med"},{"key":"1563_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/neuonc\/nov180","volume":"18","author":"W Wick","year":"2016","unstructured":"Wick W, Platten M, Wick A, Hertenstein A, Radbruch A, Bendszus M, et al. Current status and future directions of anti-angiogenic therapy for gliomas. Neuro-Oncol. 2016;18:315\u201328.","journal-title":"Neuro-Oncol."},{"key":"1563_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s13311-016-0510-y","volume":"14","author":"N Wang","year":"2017","unstructured":"Wang N, Jain RK, Batchelor TT. New directions in anti-angiogenic therapy for glioblastoma. Neurother J Am Soc Exp Neurother. 2017;14:321\u201332.","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"1563_CR7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/glia.21264","volume":"60","author":"NA Charles","year":"2012","unstructured":"Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2012;60:502\u201314.","journal-title":"Glia."},{"key":"1563_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/glia.23234","volume":"66","author":"K Turkowski","year":"2018","unstructured":"Turkowski K, Brandenburg S, Mueller A, Kremenetskaia I, Bungert AD, Blank A, et al. VEGF as a modulator of the innate immune response in glioblastoma. Glia. 2018;66:161\u201374.","journal-title":"Glia."},{"key":"1563_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0165-5728(02)00315-6","volume":"132","author":"F Forstreuter","year":"2002","unstructured":"Forstreuter F, Lucius R, Mentlein R. Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J Neuroimmunol. 2002;132:93\u20138.","journal-title":"J Neuroimmunol"},{"key":"1563_CR10","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1158\/0008-5472.CAN-07-6241","volume":"68","author":"M Kerber","year":"2008","unstructured":"Kerber M, Reiss Y, Wickersheim A, Jugold M, Kiessling F, Heil M, et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res. 2008;68:7342\u201351.","journal-title":"Cancer Res"},{"key":"1563_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00401-015-1529-6","volume":"131","author":"S Brandenburg","year":"2016","unstructured":"Brandenburg S, M\u00fcller A, Turkowski K, Radev YT, Rot S, Schmidt C, et al. Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors. Acta Neuropathol (Berl). 2016;131:365\u201378.","journal-title":"Acta Neuropathol (Berl)"},{"key":"1563_CR12","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1158\/0008-5472.CAN-14-1240","volume":"74","author":"X Chen","year":"2014","unstructured":"Chen X, Zhang L, Zhang IY, Liang J, Wang H, Ouyang M, et al. RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res. 2014;74:7285\u201397.","journal-title":"Cancer Res"},{"key":"1563_CR13","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.18632\/oncotarget.1893","volume":"5","author":"K Gabrusiewicz","year":"2014","unstructured":"Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, et al. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 2014;5:2208\u201320.","journal-title":"Oncotarget."},{"key":"1563_CR14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/neuonc\/not082","volume":"15","author":"C Lu-Emerson","year":"2013","unstructured":"Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncol. 2013;15:1079\u201387.","journal-title":"Neuro-Oncol."},{"key":"1563_CR15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/neuonc\/nos158","volume":"14","author":"Y Piao","year":"2012","unstructured":"Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-Oncol. 2012;14:1379\u201392.","journal-title":"Neuro-Oncol."},{"key":"1563_CR16","doi-asserted-by":"crossref","unstructured":"Ricard C, Stanchi F, Rougon G, Debarbieux F. An orthotopic glioblastoma mouse model maintaining brain parenchymal physical constraints and suitable for intravital two-photon microscopy. J Vis Exp. 2014;(86):51108. \n                    https:\/\/doi.org\/10.3791\/51108\n                    \n                  . PMID: 24798209","DOI":"10.3791\/51108"},{"key":"1563_CR17","doi-asserted-by":"publisher","first-page":"e72655","DOI":"10.1371\/journal.pone.0072655","volume":"8","author":"C Ricard","year":"2013","unstructured":"Ricard C, Stanchi F, Rodriguez T, Amoureux M-C, Rougon G, Debarbieux F. Dynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel density. PLoS One. 2013;8:e72655.","journal-title":"PLoS One"},{"key":"1563_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00401-014-1274-2","volume":"128","author":"R Glass","year":"2014","unstructured":"Glass R, Synowitz M. CNS macrophages and peripheral myeloid cells in brain tumours. Acta Neuropathol (Berl). 2014;128:347\u201362.","journal-title":"Acta Neuropathol (Berl)"},{"key":"1563_CR19","doi-asserted-by":"publisher","first-page":"26381","DOI":"10.1038\/srep26381","volume":"6","author":"C Ricard","year":"2016","unstructured":"Ricard C, Tchoghandjian A, Luche H, Grenot P, Figarella-Branger D, Rougon G, et al. Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice. Sci Rep. 2016;6:26381.","journal-title":"Sci Rep"},{"key":"1563_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1182\/blood.V96.2.719","volume":"96","author":"N Faust","year":"2000","unstructured":"Faust N, Varas F, Kelly LM, Heck S, Graf T. Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. Blood. 2000;96:719\u201326.","journal-title":"Blood."},{"key":"1563_CR21","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ni1139","volume":"5","author":"RL Lindquist","year":"2004","unstructured":"Lindquist RL, Shakhar G, Dudziak D, Wardemann H, Eisenreich T, Dustin ML, et al. Visualizing dendritic cell networks in vivo. Nat Immunol. 2004;5:1243\u201350.","journal-title":"Nat Immunol"},{"key":"1563_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0896-6273(00)00084-2","volume":"28","author":"G Feng","year":"2000","unstructured":"Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41\u201351.","journal-title":"Neuron."},{"key":"1563_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/B978-0-12-391857-4.00009-4","volume":"504","author":"E Meijering","year":"2012","unstructured":"Meijering E, Dzyubachyk O, Smal I. Methods for cell and particle tracking. Methods Enzymol. 2012;504:183\u2013200.","journal-title":"Methods Enzymol"},{"key":"1563_CR24","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/nprot.2015.085","volume":"10","author":"EA Susaki","year":"2015","unstructured":"Susaki EA, Tainaka K, Perrin D, Yukinaga H, Kuno A, Ueda HR. Advanced CUBIC protocols for whole-brain and whole-body clearing and imaging. Nat Protoc. 2015;10:1709\u201327.","journal-title":"Nat Protoc"},{"key":"1563_CR25","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1073\/pnas.1525360113","volume":"113","author":"J Kloepper","year":"2016","unstructured":"Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, et al. Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016;113:4476\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1563_CR26","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1158\/1078-0432.CCR-10-1868","volume":"17","author":"L von Baumgarten","year":"2011","unstructured":"von Baumgarten L, Brucker D, Tirniceru A, Kienast Y, Grau S, Burgold S, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:6192\u2013205.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1563_CR27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.immuni.2013.10.004","volume":"39","author":"S Tamoutounour","year":"2013","unstructured":"Tamoutounour S, Guilliams M, Montanana Sanchis F, Liu H, Terhorst D, Malosse C, et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity. 2013;39:925\u201338.","journal-title":"Immunity."},{"key":"1563_CR28","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.immuni.2016.08.015","volume":"45","author":"M Guilliams","year":"2016","unstructured":"Guilliams M, Dutertre C-A, Scott CL, McGovern N, Sichien D, Chakarov S, et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity. 2016;45:669\u201384.","journal-title":"Immunity."},{"key":"1563_CR29","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1038\/s41598-018-22872-y","volume":"8","author":"C Caravagna","year":"2018","unstructured":"Caravagna C, Jaou\u00ebn A, Desplat-J\u00e9go S, Fenrich KK, Bergot E, Luche H, et al. Diversity of innate immune cell subsets across spatial and temporal scales in an EAE mouse model. Sci Rep. 2018;8:5146.","journal-title":"Sci Rep"},{"key":"1563_CR30","doi-asserted-by":"publisher","first-page":"E1738","DOI":"10.1073\/pnas.1525528113","volume":"113","author":"ML Bennett","year":"2016","unstructured":"Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A. 2016;113:E1738\u201346.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1563_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","volume":"11","author":"TT Batchelor","year":"2007","unstructured":"Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83\u201395.","journal-title":"Cancer Cell"},{"key":"1563_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10:417\u201327.","journal-title":"Nat Rev Drug Discov"},{"key":"1563_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337\u201341.","journal-title":"Nature."},{"key":"1563_CR34","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41593-018-0213-2","volume":"21","author":"F Herisson","year":"2018","unstructured":"Herisson F, Frodermann V, Courties G, Rohde D, Sun Y, Vandoorne K, et al. Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat Neurosci. 2018;21:1209\u201317.","journal-title":"Nat Neurosci"},{"key":"1563_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fimmu.2015.00035","volume":"6","author":"S Gurka","year":"2015","unstructured":"Gurka S, Hartung E, Becker M, Kroczek RA. Mouse conventional dendritic cells can be universally classified based on the mutually exclusive expression of XCR1 and SIRP\u03b1. Front Immunol. 2015;6:35.","journal-title":"Front Immunol"},{"key":"1563_CR36","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1073\/pnas.1513607113","volume":"113","author":"M Kitano","year":"2016","unstructured":"Kitano M, Yamazaki C, Takumi A, Ikeno T, Hemmi H, Takahashi N, et al. Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node. Proc Natl Acad Sci U S A. 2016;113:1044\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1563_CR37","doi-asserted-by":"publisher","first-page":"13720","DOI":"10.1038\/ncomms13720","volume":"7","author":"D Laoui","year":"2016","unstructured":"Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X, Elkrim Y, et al. The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun. 2016;7:13720.","journal-title":"Nat Commun"},{"key":"1563_CR38","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.immuni.2013.02.012","volume":"38","author":"R Shechter","year":"2013","unstructured":"Shechter R, Miller O, Yovel G, Rosenzweig N, London A, Ruckh J, et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity. 2013;38:555\u201369.","journal-title":"Immunity."},{"key":"1563_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12943-018-0878-x","volume":"17","author":"T Simon","year":"2018","unstructured":"Simon T, Pinioti S, Schellenberger P, Rajeeve V, Wendler F, Cutillas PR, et al. Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma. Mol Cancer. 2018;17:132.","journal-title":"Mol Cancer"},{"issue":"4","key":"1563_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/cancers11040537","volume":"11","author":"Siddhartha Srivastava","year":"2019","unstructured":"Srivastava S, Jackson C, Kim T, Choi J, Lim M. A characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials. Cancers. 2019;11(4):537.","journal-title":"Cancers"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12974-019-1563-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-019-1563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:19:33Z","timestamp":1603757973000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-019-1563-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,28]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1186\/s12974-019-1563-8","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,28]]},"assertion":[{"value":"29 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal care guidelines: All experimental procedures were performed in accordance with French legislation and in compliance with the European Community Council Directive of November 24, 1986 (86\/609\/EEC), for the care and use of laboratory animals. The research on animals was authorized by the Direction D\u00e9partementale des Services V\u00e9t\u00e9rinaires des Bouches-du-Rh\u00f4ne (license D-13-055-21) and approved by the National Committee for Ethic in Animal Experimentation (Section no. 14; project 87\u201304122012).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}